ACHV

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical company focused on developing and commercializing cytisine, a plant-based alkaloid, for smoking cessation and nicotine addiction. Headquartered in Vancouver, Canada, with operations in Seattle, Washington, the company holds exclusive worldwide rights to develop and commercialize cytisine-based products outside of Central and Eastern Europe. The company's lead product candidate, cytisinicline, is a selective nicotinic acetylcholine receptor partial agonist that targets nicotine addiction. ACHV has completed multiple Phase 2 and Phase 3 clinical trials evaluating cytisinicline as a smoking cessation treatment, with studies demonstrating its potential efficacy and safety profile. The company's development strategy centers on advancing cytisinicline through regulatory pathways in North America and other major markets where smoking cessation therapies represent significant commercial opportunities. Cytisine has been used for smoking cessation in Central and Eastern Europe for decades, providing historical safety and efficacy data that supports ACHV's development programs. The company collaborates with contract research organizations and manufacturing partners to advance its clinical programs while maintaining a lean operational structure. As a specialty pharmaceutical company, ACHV positions itself in the smoking cessation market, which serves millions of individuals seeking to quit tobacco use globally.